David Baxter PhD
Late Founder
Schizophrenia risk for patients with cannabis-induced psychosis
Half of all patients treated for cannabis-induced psychosis may subsequently develop a schizophrenia spectrum disorder, reveal study findings that highlight the need for clinicians to recognize the prognostic significance of the condition.
The course of cannabis psychosis has been seen as benign by many experts, with symptoms thought to remit rapidly and full recovery to occur after stopping cannabis use.
Mikkel Arendt from Aarhus University Hospital in Risskov now reports that "subjects who experience psychotic symptoms that are not transient and lead to treatment seeking are at an extremely high risk of developing schizophrenia subsequently."
He told MedWire News that while temporary remission can be expected, schizophrenia can still develop some time later, often several years after cannabis-induced psychosis.
"I think that a cannabis-induced psychotic condition can often be seen as an early sign of the development of schizophrenia," he said.
Arendt and team collected information on 535 patients treated for cannabis-induced psychotic symptoms between 1994 and 1999 from national registry data.
During 3 years of follow-up, 44.5% of these individuals were diagnosed with schizophrenia spectrum disorders, and new psychotic disorders of any type, including bipolar and anxiety disorders, were diagnosed in 77.2% of individuals.
Such disorders were often delayed, occurring more than a year after seeking treatment for cannabis-induced psychosis in 47.1% of patients.
Arendt and team also found that people with cannabis-induced psychosis developed schizophrenia at a younger age than those without a history of the condition.
Among 2721 people with schizophrenia-spectrum disorders who had no history of cannabis-induced psychosis, the average age of schizophrenia onset for men was 30 years, compared with 24 years for those with cannabis-induced psychosis. Among women, onset occurred at the age of 29 and 33 years, respectively.
This suggests that cannabis use may hasten progression of schizophrenia, the researchers write in the Britsh Journal of Psychiatry.
"I think that professionals who encounter young people with cannabis-induced psychotic symptoms should offer advice to the patients and their relatives," Arendt commented.
"In addition, they should be followed closely by the treatment system, so intervention can be initiated as soon as possible if there are signs of schizophrenia.
"The earlier treatment is started the better the prognosis for the patients."
Br J Psychiatry 2005; 187: 510-515
Half of all patients treated for cannabis-induced psychosis may subsequently develop a schizophrenia spectrum disorder, reveal study findings that highlight the need for clinicians to recognize the prognostic significance of the condition.
The course of cannabis psychosis has been seen as benign by many experts, with symptoms thought to remit rapidly and full recovery to occur after stopping cannabis use.
Mikkel Arendt from Aarhus University Hospital in Risskov now reports that "subjects who experience psychotic symptoms that are not transient and lead to treatment seeking are at an extremely high risk of developing schizophrenia subsequently."
He told MedWire News that while temporary remission can be expected, schizophrenia can still develop some time later, often several years after cannabis-induced psychosis.
"I think that a cannabis-induced psychotic condition can often be seen as an early sign of the development of schizophrenia," he said.
Arendt and team collected information on 535 patients treated for cannabis-induced psychotic symptoms between 1994 and 1999 from national registry data.
During 3 years of follow-up, 44.5% of these individuals were diagnosed with schizophrenia spectrum disorders, and new psychotic disorders of any type, including bipolar and anxiety disorders, were diagnosed in 77.2% of individuals.
Such disorders were often delayed, occurring more than a year after seeking treatment for cannabis-induced psychosis in 47.1% of patients.
Arendt and team also found that people with cannabis-induced psychosis developed schizophrenia at a younger age than those without a history of the condition.
Among 2721 people with schizophrenia-spectrum disorders who had no history of cannabis-induced psychosis, the average age of schizophrenia onset for men was 30 years, compared with 24 years for those with cannabis-induced psychosis. Among women, onset occurred at the age of 29 and 33 years, respectively.
This suggests that cannabis use may hasten progression of schizophrenia, the researchers write in the Britsh Journal of Psychiatry.
"I think that professionals who encounter young people with cannabis-induced psychotic symptoms should offer advice to the patients and their relatives," Arendt commented.
"In addition, they should be followed closely by the treatment system, so intervention can be initiated as soon as possible if there are signs of schizophrenia.
"The earlier treatment is started the better the prognosis for the patients."
Br J Psychiatry 2005; 187: 510-515